A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Document Type
Conference Proceeding
Publication Date
1-11-2026
Publication Title
Journal of Clinical Oncology
First Page
TPS273
Last Page
TPS273
Volume
44
Publisher
American Society of Clinical Oncology
Rights
Copyright © 2026 by the American Society of Clinical Oncology
Recommended Citation
Arshad, Tariq; Gazda, Michael; Tapolsky, Gilles; Beach, Jim; Flora, Daniel Blake; Patel, Reema Anil; Lee, Fa-Chyi; Flora, Douglas B.; Sohal, Davendra; Sharif, Saima; Chung, Ki Young; Villano, John L.; Sharma, Vivek; Gemmill, Julie Anne L.; Pimentel, Agustin; Gabrail, Nashat Y.; Outlaw, Darryl Alan; Baron, Ari David; and Boulmay, Brian C., "A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma." (2026). School of Medicine Faculty Publications. 4825.
https://digitalscholar.lsuhsc.edu/som_facpubs/4825
10.1200/JCO.2026.44.2_suppl.TPS273